Senolytic, mitochondrial, and longevity research tools.

Longevity research compounds — including senolytic peptides, mitochondrial-derived peptides (MDPs), and pineal-axis short peptides — are studied in preclinical research models for cellular senescence pathways, mitochondrial bioenergetics, and aging-research applications. The Nexus catalog includes 7 compounds in this category — examples: Epithalon, FOXO4, Humanin, MOTS-c, NAD+. Supplied for in-vitro research use only.

Longevity and cellular health research products include senescence, mitochondrial, redox, and cellular-signaling compounds. Nexus separates this group from general energy research because the discovery intent is often cell-health comparison rather than acute energy-metabolism framing.

This category includes Epithalon, FOXO4, Humanin, MOTS-c, NAD+, SS-31, and PNC-27. Each product is presented as a research material with conservative copy and batch-first verification signals.

This category is built around cellular pathways, mitochondrial signaling, redox models, and senescence-adjacent research. Some products overlap conceptually with energy metabolism, but Nexus uses this landing page for longer-horizon cellular-health discovery.

Product pages keep the comparison practical: name, format, variant size, COA context, molecular data where available, and related internal links. The category avoids unsupported anti-aging or treatment language.

Nexus surfaces lab-tested context and COA access where possible. Cellular-health products can attract exaggerated claims, so copy is intentionally factual and tied to research identity rather than consumer outcomes.

Compounds in this category are studied in preclinical research models examining cellular senescence, mitochondrial bioenergetics, NAD+ pathway research, and aging-research applications. Common research applications include epithalon research on pineal-axis longevity signaling, FOXO4-DRI research on senolytic pathway research, MOTS-c and humanin research on mitochondrial-derived peptide signaling, SS-31 (elamipretide) research on mitochondrial-targeted antioxidant peptide research, NAD+ research as a mitochondrial bioenergetics substrate, and PNC-27 research on p53-derived peptide research.

The seven compounds span four mechanism sub-families: pineal-axis short peptides (epithalon), senolytic peptides (FOXO4-DRI), mitochondrial-derived peptides (MOTS-c, humanin), mitochondrial-targeted peptides (SS-31), p53-derived peptides (PNC-27), and NAD+ pathway compounds (NAD+ itself). Molecular weight ranges from 390 Da (epithalon) to 2.5 kDa (humanin).

Common research-stack pairings: epithalon + pinealon for pineal-axis research (pinealon is in Russian Bioregulators); MOTS-c + humanin for mitochondrial-derived peptide research; NAD+ + MOTS-c for mitochondrial bioenergetics research; FOXO4-DRI + epithalon for senescence-and-pineal-axis research combinations.

Mitochondrial peptides (MOTS-c, humanin) and the SS-31 research peptide are mid-size (1-2.5 kDa) and characterized by standard HPLC + ESI-MS. Epithalon at 390 Da is the smallest peptide in this category and requires short-peptide-specific HPLC methods. NAD+ is a nucleotide, not a peptide — characterized by HPLC + UV spectroscopy.